Publications by authors named "P Panagakis"
Real-world effectiveness and drug survival of guselkumab over a period of 3 years in moderate-to-severe plaque psoriasis, including difficult-to-treat areas.
Natalia Rompoti Theognosia Vergou Irene Stefanaki Charitomeni Vavouli Ioannis-Alexios Koumprentziotis Pantelis Panagakis
Int J Dermatol
October 2024
Article Synopsis
- Bimekizumab is a monoclonal antibody that targets interleukin-17A and interleukin-17F, proving to be very effective for treating chronic plaque psoriasis with a quick impact based on Randomized Controlled Trials (RCTs).
- A study in Athens involved 61 patients with moderate-to-severe psoriasis, revealing that a significant percentage achieved marked improvement (PASI75: 65.7%, PASI90: 45.7%, PASI100: 32.4%) after just 4 weeks and even higher rates after 16 weeks.
- The safety profile showed a few mild-to-moderate adverse events, including oral candidiasis, aligning with
Real-world data on the effectiveness of brodalumab in patients with moderate-to severe plaque psoriasis in the Greek clinical setting (the BrIDGE study).
Dimitrios Rigopoulos Eleftheria Tampouratzi Charalampos Angelakopoulos Zoe Apalla Ioannis Barkis Pantelis Panagakis
J Eur Acad Dermatol Venereol
June 2024
Article Synopsis
- - The BrIDGE study examined the real-world effectiveness of brodalumab in treating moderate-to-severe plaque psoriasis in Greece, focusing on the percentage of patients achieving complete clearance (PASI100) over 24 weeks and beyond.
- - Results showed that 42% of patients reached PASI100 at Week 24, with this number increasing to 65% by Week 104, while significant improvements were noted in other assessment scores (PASI75, PASI90, and sPGA).
- - Additionally, patients reported improved quality of life, with average scores on the Dermatology Life Quality Index (DLQI) decreasing significantly over the study period, indicating better overall well-being as a result of brodalumab treatment